OraLiva, Inc. has recently unveiled a groundbreaking innovation in the field of oral cancer detection: an AI-powered oral cancer and lesion test. This non-invasive tool is designed to revolutionize the way dentists and clinicians identify and monitor oral cancer, offering a more proactive approach to early detection. With a focus on precision and accessibility, OraLiva's test is poised to make a significant impact on oral healthcare.
A Thermometer for Cancer
The test, aptly named a "thermometer for cancer," is intended for use by a wide range of dental professionals, including dentists, periodontists, oral and maxillofacial surgeons, and ENTs. Its simplicity and effectiveness make it a valuable addition to routine clinical practice. Samples are collected quickly and easily with a simple brush of the lesion during a regular dental visit, ensuring minimal disruption to patients.
OraLiva's test is built upon a massive NIH-sponsored study, involving 999 patients and over 13 million analyzed cells. This extensive research has led to the development of a highly advanced cytology model, capable of accurately distinguishing between mild, moderate, and severe oral epithelial dysplasia, a key indicator of pre-cancerous conditions.
Overcoming Diagnostic Challenges
Oral cancer, despite being visible in routine dental examinations, remains a formidable challenge to detect early. Many benign oral lesions share features with oral epithelial dysplasia, making it difficult for clinicians to differentiate between the two. This diagnostic dilemma is further exacerbated by the lack of readily available tools to guide front-line healthcare providers in evaluating suspicious lesions.
In 2025, an estimated 59,660 Americans will be diagnosed with oral cancer, with approximately 12,770 deaths attributed to the disease. Alarmingly, only one in four cases are detected at an early stage, where survival rates are significantly higher. Most oral cancer cases are diagnosed at later stages, significantly reducing survival prospects. This stark reality underscores the urgent need for improved early-identification tools.
OraLiva's test addresses this critical gap by not only supporting the detection of cancerous lesions but also by intercepting disease at the precancerous dysplasia stage. This early intervention is crucial, as it allows for less invasive treatments, improved survival rates, and significantly reduced healthcare costs.
A Novel Cytomics Platform
At the heart of OraLiva's test is a cutting-edge cytomics platform that combines advanced microfluidics, high-resolution cellular imaging, and artificial intelligence. This innovative technology enables the analysis of cellular changes associated with early cancer development, providing a comprehensive understanding of the disease's progression.
After sample collection, the process continues in OraLiva's lab. Here, a proprietary microfluidic cartridge prepares the sample for digital cytology analysis. The system then generates high-resolution cellular images, capturing detailed morphological and biomarker information from individual epithelial cells. These images are analyzed by AI models, trained on millions of oral epithelial cells, to detect subtle cellular patterns indicative of dysplasia and malignancy.
The resulting test report, reviewed and approved by a pathologist, provides a quantitative risk score and actionable recommendations. This comprehensive approach ensures that dental providers receive clear guidance on whether to rule out, monitor, or refer patients, empowering them to make informed decisions.
Access and Partnership
OraLiva has strategically partnered with Delta Dental of Michigan, Indiana, Ohio, and North Carolina to make the test available to providers in these states as a covered procedure under CDT code D7288 (brush biopsy, transepithelial sample collection). This partnership aims to expand access to early detection methods, ultimately improving oral cancer outcomes.
Dental providers interested in evaluating the technology can sign up for clinical evaluation kits, marking a significant step towards widespread adoption and improved oral healthcare.
About OraLiva, Inc.
OraLiva is a forward-thinking company dedicated to developing AI-powered cytology diagnostics for early detection across epithelial tissues. Their oral lesion test is a testament to their commitment to innovation, combining microfluidic cytology collection, digital imaging, and artificial intelligence to generate clinically validated, risk-stratified reports. These reports provide actionable recommendations that support clinical decision-making, ultimately improving patient outcomes.
In conclusion, OraLiva's AI-powered oral cancer and lesion test represents a significant advancement in oral healthcare. By addressing the challenges of early detection and providing accessible, precise tools, OraLiva is poised to make a substantial impact on the fight against oral cancer, ultimately improving the lives of patients and healthcare providers alike.
